AITC—a potent TRPA1 agonist—increases glucose uptake, improves insulin signaling, and mitochondrial function, and reduces the expression of obesity-induced associated inflammation factors TNF-α, and IL-6 (Derbenev and Zsombok, 2016). Here, TRPA1 is linked to obesity due to melanocortin 4 receptor deficiency.